guest ::
| Home > Publications database > Neoadjuvant Therapy in Rectal Cancer Patients With Clinical Stage II to III Across European Countries: Variations and Outcomes. > print |
| Home > Publications database > Neoadjuvant Therapy in Rectal Cancer Patients With Clinical Stage II to III Across European Countries: Variations and Outcomes. > print |
| 001 | 132624 | ||
| 005 | 20240229105023.0 | ||
| 024 | 7 | _ | |a 10.1016/j.clcc.2017.09.002 |2 doi |
| 024 | 7 | _ | |a pmid:29074354 |2 pmid |
| 024 | 7 | _ | |a 1533-0028 |2 ISSN |
| 024 | 7 | _ | |a 1938-0674 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2018-00284 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Babaei, Masoud |0 P:(DE-HGF)0 |b 0 |e First author |
| 245 | _ | _ | |a Neoadjuvant Therapy in Rectal Cancer Patients With Clinical Stage II to III Across European Countries: Variations and Outcomes. |
| 260 | _ | _ | |a Dallas, Tex. |c 2018 |b Cancer Information Group |
| 264 | _ | 1 | |3 print |2 Crossref |b Elsevier BV |c 2018-03-01 |
| 264 | _ | 1 | |3 print |2 Crossref |b Elsevier BV |c 2018-03-01 |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1659445581_15545 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Neoadjuvant therapy improves survival of patients with clinical stage II and III rectal cancer in clinical trials. In this study, we investigated the administration of neoadjuvant radiotherapy (neo-RT) and neoadjuvant chemoradiotherapy (neo-CRT) and its association with survival in resected patients in 2 European countries (The Netherlands and Sweden) and at 3 specialist centers.Administration of neoadjuvant treatment (all registries) and overall survival after surgery in The Netherlands and Sweden were assessed. Hazard ratios (HRs) were obtained using Cox regression adjusted for potential confounders.A total of 16,095 rectal cancer patients with clinical stage II and III were eligible for analyses. Large variations in administration of neo-RT and neo-CRT were observed. Elderly patients less often received neo-RT and neo-CRT. Patients with stage III disease received neo-CRT more frequently than neo-RT. Administration of neo-RT versus surgery without neoadjuvant treatment was significantly associated with improved survival in The Netherlands (HR, 0.62; 95% confidence interval [CI], 0.53-0.73) as well as in Sweden (HR, 0.79; 95% CI, 0.69-0.90). Administration of neo-CRT was associated with enhanced survival in The Netherlands (HR, 0.62; 95% CI, 0.50-0.78) but not in Sweden (HR, 0.97; 95% CI, 0.80-1.18). The mortality of patients treated with neo-CRT compared with neo-RT showed inconsistent results in population-based centers.Our results support an association of neo-RT with enhanced survival among stage II and III rectal cancer patients. Comparing neo-CRT with neo-RT, larger variations and inconsistent results with respect to survival were observed across centers. |
| 536 | _ | _ | |a 313 - Cancer risk factors and prevention (POF3-313) |0 G:(DE-HGF)POF3-313 |c POF3-313 |f POF III |x 0 |
| 542 | _ | _ | |i 2018-03-01 |2 Crossref |u https://www.elsevier.com/tdm/userlicense/1.0/ |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Jansen, Lina |b 1 |
| 700 | 1 | _ | |a Balavarca, Yesilda |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Sjövall, Annika |b 3 |
| 700 | 1 | _ | |a Bos, Amanda |b 4 |
| 700 | 1 | _ | |a van de Velde, Tony |b 5 |
| 700 | 1 | _ | |a Moreau, Michel |b 6 |
| 700 | 1 | _ | |a Liberale, Gabriel |b 7 |
| 700 | 1 | _ | |a Gonçalves, Ana Filipa |b 8 |
| 700 | 1 | _ | |a Bento, Maria José |b 9 |
| 700 | 1 | _ | |a Ulrich, Cornelia M |0 P:(DE-HGF)0 |b 10 |
| 700 | 1 | _ | |a Schrotz-King, Petra |0 P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86 |b 11 |u dkfz |
| 700 | 1 | _ | |a Lemmens, Valery |b 12 |
| 700 | 1 | _ | |a Glimelius, Bengt |b 13 |
| 700 | 1 | _ | |a Brenner, Hermann |0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2 |b 14 |e Last author |u dkfz |
| 773 | 1 | 8 | |a 10.1016/j.clcc.2017.09.002 |b Elsevier BV |d 2018-03-01 |n 1 |p e129-e142 |3 journal-article |2 Crossref |t Clinical Colorectal Cancer |v 17 |y 2018 |x 1533-0028 |
| 773 | _ | _ | |a 10.1016/j.clcc.2017.09.002 |g Vol. 17, no. 1, p. e129 - e142 |0 PERI:(DE-600)2572502-6 |n 1 |p e129-e142 |t Clinical colorectal cancer and other gastrointestinal malignancies |v 17 |y 2018 |x 1533-0028 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:132624 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 11 |6 P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 14 |6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-313 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Cancer risk factors and prevention |x 0 |
| 914 | 1 | _ | |y 2018 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CLIN COLORECTAL CANC : 2013 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 920 | 1 | _ | |0 I:(DE-He78)C070-20160331 |k C070 |l C070 Klinische Epidemiologie und Alternf. |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)G110-20160331 |k G110 |l Präventive Onkologie |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)L101-20160331 |k L101 |l DKTK Heidelberg |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C070-20160331 |
| 980 | _ | _ | |a I:(DE-He78)G110-20160331 |
| 980 | _ | _ | |a I:(DE-He78)L101-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| 999 | C | 5 | |a 10.6004/jnccn.2015.0087 |9 -- missing cx lookup -- |1 Benson |p 719 - |2 Crossref |t J Natl Compr Canc Netw |v 13 |y 2015 |
| 999 | C | 5 | |a 10.3109/0284186X.2013.764008 |9 -- missing cx lookup -- |1 Maringe |p 919 - |2 Crossref |t Acta Oncol |v 52 |y 2013 |
| 999 | C | 5 | |a 10.1093/annonc/mds236 |9 -- missing cx lookup -- |1 Schmoll |p 2479 - |2 Crossref |t Ann Oncol |v 23 |y 2012 |
| 999 | C | 5 | |a 10.1093/annonc/mdt240 |9 -- missing cx lookup -- |1 Glimelius |p vi81 - |2 Crossref |t Ann Oncol |v 24 |y 2013 |
| 999 | C | 5 | |a 10.1136/bmj.d6751 |9 -- missing cx lookup -- |1 Poston |p d6751 - |2 Crossref |t BMJ |v 343 |y 2011 |
| 999 | C | 5 | |a 10.1093/annonc/mdu245 |9 -- missing cx lookup -- |1 Valentini |p 1863 - |2 Crossref |t Ann Oncol |v 25 |y 2014 |
| 999 | C | 5 | |a 10.3109/03009734.2012.658974 |9 -- missing cx lookup -- |1 Glimelius |p 225 - |2 Crossref |t Ups J Med Sci |v 117 |y 2012 |
| 999 | C | 5 | |a 10.6004/jnccn.2012.0158 |9 -- missing cx lookup -- |1 Benson |p 1528 - |2 Crossref |t J Natl Compr Canc Netw |v 10 |y 2012 |
| 999 | C | 5 | |a 10.1016/j.ejso.2014.09.011 |9 -- missing cx lookup -- |1 van den Broek |p 1789 - |2 Crossref |t Eur J Surg Oncol |v 40 |y 2014 |
| 999 | C | 5 | |1 McVie |y 2012 |2 Crossref |o McVie 2012 |
| 999 | C | 5 | |1 Fritz |y 2000 |2 Crossref |o Fritz 2000 |
| 999 | C | 5 | |a 10.1245/s10434-013-3198-9 |9 -- missing cx lookup -- |1 Rahbari |p 4169 - |2 Crossref |t Ann Surg Oncol |v 20 |y 2013 |
| 999 | C | 5 | |1 Peev |y 2015 |2 Crossref |o Peev 2015 |
| 999 | C | 5 | |a 10.3109/0284186X.2010.506884 |9 -- missing cx lookup -- |1 Valentini |p 1206 - |2 Crossref |t Acta Oncol |v 49 |y 2010 |
| 999 | C | 5 | |a 10.1016/j.clon.2010.03.002 |9 -- missing cx lookup -- |1 Wong |p 265 - |2 Crossref |t Clin Oncol (R Coll Radiol) |v 22 |y 2010 |
| 999 | C | 5 | |1 McCarthy |y 2012 |2 Crossref |o McCarthy 2012 |
| 999 | C | 5 | |1 De Caluwe |y 2013 |2 Crossref |o De Caluwe 2013 |
| 999 | C | 5 | |a 10.1200/JCO.2007.15.3858 |9 -- missing cx lookup -- |1 Braendengen |p 3687 - |2 Crossref |t J Clin Oncol |v 26 |y 2008 |
| 999 | C | 5 | |a 10.1093/annonc/mdv331 |9 -- missing cx lookup -- |1 Jiang |p 2102 - |2 Crossref |t Ann Oncol |v 26 |y 2015 |
| 999 | C | 5 | |a 10.1016/j.critrevonc.2008.11.006 |9 -- missing cx lookup -- |1 Aparicio |p 249 - |2 Crossref |t Crit Rev Oncol Hematol |v 71 |y 2009 |
| 999 | C | 5 | |a 10.1016/j.ejso.2016.05.020 |9 -- missing cx lookup -- |1 Elliot |p 1667 - |2 Crossref |t Eur J Surg Oncol |v 42 |y 2016 |
| 999 | C | 5 | |1 Pasetto |y 2006 |2 Crossref |o Pasetto 2006 |
| 999 | C | 5 | |a 10.1007/s00268-015-3319-7 |9 -- missing cx lookup -- |1 Bergquist |p 447 - |2 Crossref |t World J Surg |v 40 |y 2016 |
| 999 | C | 5 | |a 10.1016/S1470-2045(14)71199-4 |9 -- missing cx lookup -- |1 Breugom |p 200 - |2 Crossref |t Lancet Oncol |v 16 |y 2015 |
| 999 | C | 5 | |a 10.1016/j.ejso.2015.03.233 |9 -- missing cx lookup -- |1 Bujko |p 713 - |2 Crossref |t Eur J Surg Oncol |v 41 |y 2015 |
| 999 | C | 5 | |a 10.3109/0284186X.2014.993768 |9 -- missing cx lookup -- |1 Poulsen |p 437 - |2 Crossref |t Acta Oncol |v 54 |y 2015 |
| 999 | C | 5 | |a 10.1016/j.ejca.2013.06.048 |9 -- missing cx lookup -- |1 van de Velde |p 1.e1 - |2 Crossref |t Eur J Cancer |v 50 |y 2014 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|